Adherex Technologies (NASDAQ:FENC – Get Free Report) will likely be announcing its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Adherex Technologies to announce earnings of $0.02 per share and revenue of $16.2060 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:30 AM ET.
Adherex Technologies (NASDAQ:FENC – Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.03. Adherex Technologies had a negative return on equity of 43.87% and a negative net margin of 17.12%.The firm had revenue of $15.11 million for the quarter, compared to the consensus estimate of $13.90 million. On average, analysts expect Adherex Technologies to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Adherex Technologies Price Performance
Shares of FENC stock opened at $11.57 on Friday. The business’s fifty day moving average price is $10.00 and its 200 day moving average price is $8.48. Adherex Technologies has a 1-year low of $5.65 and a 1-year high of $11.66. The firm has a market capitalization of $405.64 million, a PE ratio of -39.90 and a beta of 1.09.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on Adherex Technologies
Institutional Trading of Adherex Technologies
A hedge fund recently bought a new stake in Adherex Technologies stock. Jane Street Group LLC bought a new stake in shares of Adherex Technologies Inc. (NASDAQ:FENC – Free Report) during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 14,718 shares of the company’s stock, valued at approximately $90,000. Jane Street Group LLC owned about 0.05% of Adherex Technologies as of its most recent filing with the SEC. 55.51% of the stock is owned by hedge funds and other institutional investors.
Adherex Technologies Company Profile
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.
Read More
- Five stocks we like better than Adherex Technologies
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for Adherex Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
